Estrogen Replacement TherapyHormone Replacement TherapyProgestinsEstrogens, Conjugated (USP)PostmenopauseHormonesMenopauseEstrogensMedroxyprogesterone AcetateThyroid HormonesFollicle Stimulating HormoneHuman Growth HormoneGonadal Steroid HormonesLuteinizing HormoneGonadotropin-Releasing HormoneBreast NeoplasmsHot FlashesAntineoplastic Agents, HormonalParathyroid HormoneNorpregnenesMedroxyprogesteroneEstradiolWomen's HealthAndrogen AntagonistsProgesterone CongenersReceptors, Thyroid HormoneAdrenocorticotropic HormoneNorethindroneProgesteroneNeoplasms, Hormone-DependentRisk FactorsProstatic NeoplasmsPituitary HormonesGynecologyTestosteroneOvariectomyMammographyEstoniaGoserelinReceptors, EstrogenTriiodothyronineReceptors, ProgesteroneRandomized Controlled Trials as TopicEstradiol CongenersThyrotropinThyroxineLeuprolideJuvenile HormonesTamoxifenFlutamideHysterectomyOrchiectomyPerimenopauseClimactericAndrostenesGrowth DisordersTurner SyndromeDydrogesteroneFollow-Up StudiesGrowth Hormone-Releasing HormoneTosyl CompoundsAdministration, CutaneousTime FactorsMetrorrhagiaBreastAromatase InhibitorsProspective StudiesCase-Control StudiesCorticotropin-Releasing HormoneAndrogensIncidenceHypothalamic HormonesPeptide HormonesEndometrial NeoplasmsPituitary GlandCohort StudiesLentinulaAge FactorsAnti-Mullerian HormoneGonadal HormonesProportional Hazards ModelsThyroid Hormone Receptors betaCarcinoma, LobularRiskTreatment OutcomeProlactinPrepaid Health PlansNitrilesMegestrol AcetateOsteoporosis, PostmenopausalPituitary Hormones, AnteriorCarcinoma, Ductal, BreastWithholding TreatmentNew MexicoUnited StatesTherapeutic MisconceptionRisk AssessmentDouble-Blind MethodEstrogen Receptor alphaEstrone